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Abstract: Traditional methods of chemical synthesis of alkaloids 
exhibit various problems such as lack of enantioselectivity, the 
use of toxic chemical and intermediates, and multiple numbers of 
synthetic steps. Consequently, various enzymatic methods for the 
formation of C-C bonds in the alkaloid skeleton have been 
developed. Herein, we report advances achieved in the enzymatic 
or chemo-enzymatic synthesis of pharmaceutically important 
alkaloids that employ three C-C bond forming enzymes: two 
Pictet-Spenglerases and the oxidative C-C bond forming 
flavoenzyme Berberine Bridge Enzyme. Protein engineering 
studies, improving the substrate scope of these enzymes, and 
thereby leading to the synthesis of non-natural alkaloids 
possessing higher or newer pharmacological activities, are also 
discussed. Furthermore, the integration of these biocatalysts with 
other enzymes, in multi-enzymatic cascades for the 
enantioselective synthesis of alkaloids, is also reviewed. Current 
results suggest that these enzymes hold great promise for the 
generation of C-C bonds in the selective synthesis of alkaloid 
compounds possessing diverse pharmacological properties. 
1. Introduction 
Plant secondary metabolites of the alkaloid class are 
indispensable constituents of natural products possessing a 
diverse range of pharmacological activities.[1,2] Alkaloids comprise 
about 15.6% of known natural products, and constitute almost 
50% of pharmaceutically important natural products of plant 
origin.[3] Of their many important structural types, monoterpene 
indole [MIAs] and benzylisoquinoline alkaloids are of special 
interest owing to the diverse array of pharmacological activities 
exhibited by their members. For instance, the FDA-approved 
antihypertensive agent reserpine, anti-tumor drugs such 
vinorelbine, vinblastine and vincristine all belong to the MIA class 
of alkaloids.[4,5] Similarly, members of the benzylisoquinoline class, 
atracurium, mivacurium and cisatracurium have been approved 
as muscle relaxants by the FDA.[4,6] 
Owing to their plant origin, alkaloids are not always 
accumulated at high concentrations. Therefore, isolation and 
purification of trace amounts of pharmaceutically important 
alkaloids from their natural hosts is limited by cost factors.[7] Thus, 
the chemical synthesis of these natural products and their 
analogues is of special interest. Though significant developments 
have been achieved in recent years for chemical transformations 
for the synthesis of alkaloids,[8,9] these methods display numerous 
disadvantages from the perspective of sustainable chemistry. 
Furthermore, the highly complex structures of alkaloids, and the 
presence of multiple chiral centers within the structures, also 
present challenges to the chemical synthesis of these compounds. 
It has also been reported that many pharmaceutical companies 
have given up on the screening of chemically synthesized libraries 
of natural products as potential drug hits consequent of two 
reasons, - µ3RRU V\QWKHWLF \LHOGV¶ DQG µLPSUDFWLFDOLW\ RI VFDOH-
XS¶[10-12] 
Despite the potential challenges, there is a resurgence of 
interest in the drug discovery process regarding natural products 
owing to the unmatched potential of these compounds.[11-13] 
Moreover, with recent developments in molecular biology, many 
of the biosynthetic pathways for alkaloid production in plants have 
been studied at the molecular level.[6] This has enabled the design 
of various biocatalytic synthetic strategies by employing important 
enzymes involved in the alkaloid production.[14] Enzymatic 
strategies reduce the use of hazardous toxic chemical and 
LQWHUPHGLDWHV WKHUHE\ SURYLGLQJ D µJUHHQHU¶ DOWHUQDWLYH WR WKH
traditional chemical syntheses.[15-19] Furthermore, a surge in 
demand for enantiopure pharmaceuticals, owing to the 
regulations imposed by various regulatory agencies, can be 
addressed using the exquisite mixture of enantio-, regio- and, 
chemoselectivity displayed by enzymes.[20,21] Enzymes can also 
be employed in multi-enzymatic one-pot cascades which can 
execute the synthesis of complex compounds from cheaper 
starting materials, most importantly, avoiding the purification of 
the intermediates.[22-25] 
This review focuses on recent studies on the role of C-C 
bond forming enzymes such as Pictet-Spenglerases i.e. 
Strictosidine synthase (STR) and Norcoclaurine synthase (NCS) 
and an oxidative C-C bond catalyzing enzyme Berberine bridge 
enzyme (BBE), in the chemo-enzymatic synthesis of 
pharmaceutically important alkaloids. The review also takes a 
closer look at recent advances in the understanding of protein 
structure and protein engineering, which have been shown to 
improve the substrate scope of these enzymes, leading to the 
synthesis of non-natural alkaloids possessing superior or 
alternative pharmacological activity. The synthetic applications of 
these biocatalysts along with other enzymes, in multi-enzymatic 
cascades, are also discussed.  
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Prof. Grogan works on the identification, 
characterisation and application of new 
enzymes that have potential applications in 
biotechnology, including those for the 
production of chiral pharmaceutical 
precursors and the bioprocessing of 
renewable materials. The research of Prof. 
Grogan is mainly focused on a 
multidisciplinary approach involving synthetic 
chemistry, microbiology, molecular biology, and X-ray crystallography, with 
a view to engineering important enzymes in chiral amine synthesis such as 
imine reductases, amine oxidases and Cytochromes P450s for altered or 
improved characteristics. 
 
 3URI <XQ¶V PDMRU UHVHDUFK LV IRFXVHG RQ
method development of protein engineering 
based on unnatural amino acid mutagenesis 
and biotechnological production of chiral 
compounds, bioactive molecules and 
bioplastics by using enzyme technology, 
enzyme engineering, whole-cell biocatalyst 
and synthetic biology. The specific research 
LQWHUHVW RI 3URI <XQ¶V ODE LV WKH SURFHVV
development for enantioselective synthesis of unnatural amino acids, nylon 
monomers, chiral amines, and other pharmaceutically important 
compounds . 
2. Pictet-Spenglerases 
The Pictet-Spengler reaction is the acid-catalyzed 
electrophilic addition of an iminium ion to a substituted aryl 
species (Figure 1A) and was first reported in 1911 by Amé Pictet 
and Theodor Spengler.[26] The Pictet±Spengler reaction consists 
of two steps: In the first step, an iminium intermediate is generated 
by the acid catalyzed condensation between the aldehyde and an 
electronic-rich aromatic amine; In the second step a Mannich-type 
electrophilic aromatic substitution reaction occurs, in which intra-
molecular attack of the activated aromatic ring to the new double 
bond yields a positively charged intermediate, which is 
subsequently deprotonated to yield the ȕ-carboline products[27-32] 
(Figure 1B). 
The Pictet-Spengler reaction has been utilized for the 
synthesis of a diverse range of alkaloids and key intermediates 
WKHUHRIVXFKDVȕ-carboline and isoquinoline derivatives. These 
alkaloids are the constituents of many important pharmaceuticals. 
)RU LQVWDQFH WKH ȕ-carboline scaffold is a part of numerous 
agonists and inverse agonists of benzodiazepine 
receptor.[28,29,33,34] Benzodiazepine receptors play a pivotal role in 
the control of important physiological phenomena such as, 
anxiety,[35] memory learning,[36] and sleep.[37,38] While agonists of 
Benzodiazepine receptor are clinically used as anticonvulsants 
and myorelaxants, inverse agonists are used as anxiogenics and 
samnolytics. Similarly, the isoquinoline scaffold is a constituent of 
many pharmaceutically important alkaloids, such as the analgesic 
codeine, the muscle relaxant papaverine, the antibiotic 
sanguinarine, and the antineoplastic noscapine.[39]  
 
Figure 1. A) Acid catalyzed Pictet-Spengler condensation reaction; and B) 
Mechanism of the Pictet-Spengler reaction 
While significant achievements in the chemical synthesis of 
alkaloid synthesis using the Pictet±Spengler condensation were 
achieved in subsequent years, the first enzyme catalyzing the 
Pictet±Spengler reaction was discovered in 1977.[40,41] Pictet-
Spenglerases are unique enzymes per se because the chirality in 
alkaloid products is introduced with the formation of an 
asymmetric C-C bond.[42-44] The Pictet-Spenglerase group of 
enzymes consists of four important enzymes: Deacetylipecoside 
synthase (DAPS), Deacetylisoipecoside synthase (DAIPS), 
Norcoclaurine synthase (NCS) and Strictosidine synthase 
(STR).[44,45] While both Deacetylipecoside synthase and 
Deacetylisoipecoside synthase have not been well characterized, 
both Norcoclaurine synthase and Strictosidine synthase have 
been the subject of intensive studies with respect to their roles, 
structure, mechanism and application, in the synthesis of 
chemically and pharmaceutically important alkaloids.   
 
2.1. Strictosidine synthase 
Strictosidine synthase (STR; E.C. 4.3.3.2) was the first 
Pictet-Spenglerase to be identified, and was partially purified from 
Catharanthus roseus.[46,47] Although subsequent studies purified 
the STR in homogenous form from Catharanthus cell 
suspensions, the preparation consisted of isozymes having 
similar physical and kinetic properties.[48] The STR purified from 
cell cultures of Rauvolfia serpentina, by contrast, was shown to 
be a single enzyme.[49] STR, the first enzyme of the terpene-indole 
alkaloid pathway, is known to catalyze a Pictet-Spengler reaction 
between secologanin and tryptamine to form strictosidine with the 
3-Į-(S)-configuration.[50,51] Isotopic labeling of strictosidine has 
demonstrated that strictosidine serves as the sole precursor in the 
biosynthesis of more than 2,000 monoterpene indole alkaloids  
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Figure 2. Role of strictosidine as a central precursor in the synthesis of diverse range of pharmacologically important MIAs 
[MIAs], a structurally diverse family of natural products that 
includes pharmaceutically valuable compounds, such as ajmaline, 
ajmalicine, vinblastine, vincristine, and camptothecin[42,48,52,53]  
(Figure 2). A taxonomic survey of STR distribution later confirmed 
the exclusive occurrence of STR in plants producing indole 
alkaloids.[54] 
2.1.1 Structure of STR 
The first crystal structure of an STR was obtained for the 
enzyme from the Indian medicinal plant R. serpentina by Ma et 
al.[55] In these studies, the crystal structures of R. serpentina STR 
(STR-Rs) and its complex with the natural substrates tryptamine 
[PDI ID: 2FPB] and secologanin [PDI ID: 2FPC] were reported. 
The structure of STR-Rs was reported to contain a six-bladed 
four-VWUDQGHGȕ-propeller fold and all the six blades are radially 
arranged around a pseudo six-fold symmetry axis (Figure 3A). 
Each blade was also reported to contain a twisted four-stranded 
DQWLSDUDOOHOȕ-sheet. STR-Rs also contains three helical segments. 
The first two helices are located in the loop that connects the two 
blades (blade-1 and blade-2). The third helix is a part of blade-3, 
and together with the loop region of blade-5, was presumed to 
form a cap over the catalytic center of STR.[56] 
 
Figure 3. A) Structure of six-bladed ȕ-propeller fold of STR-Rs in complex with 
tryptamine [PDI ID: 2FPB]; and B) The interaction of catalytic residues of STR 
with tryptamine substrate [55]  
These crystal structures provided deeper insights into the 
architecture of the active site, and the nature of the substrate 
binding pocket. The active site of STR-Rs contains three ionizable 
residues, Tyr151, His307, and Glu309[55] (R. serpentina 
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numbering) (Figure 3B). To establish the specific role of these 
residues, a site-directed mutagenesis approach was employed 
wherein it was found that a change of Tyr151 to phenylalanine did 
not significantly alter the catalytic activity, implying that the 
ionizable hydroxyl group does not play a key role in catalysis.[55] 
Furthermore, the decrease of catalytic activity by 900-fold, 
following site-directed mutagenesis of Glu309, supported the 
involvement of this residue in enzyme catalysis.[55] Also, the 
crystal structure revealed that His307 is involved in the binding to 
the glucose moiety of secologanin and site-directed mutagenesis 
of His307 to alanine resulted in a significant increase in the Km 
values for secologanin.[55]  
Further ab initio and crystallographic studies by Maresh et 
al.[57] provided insight into the nature of the binding site, and the 
productive transition states involved in the reaction of STR from 
C. roseus (STR-Cr; 89% homology to STR-Rs). The pH 
dependence of the solution and enzymatic reactions provided 
evidence for a sequence of acid-base catalysis steps in the STR-
catalyzed reaction. These studies suggested that Glu309 plays 
the important role of general acid catalyst in STR-mediated 
catalysis and is responsible for protonation of the carbinolamine 
to result in iminium formation. Protonated tryptamine 
subsequently enters the active site, and transfers its proton to 
Glu309, thereby supplying the proton for acid-catalysis.[57] Also, 
Glu309 was presumed to be responsible for the final 
deprotonation step, since no other appropriate residues appeared 
to perform this role.  
The Kinetic Isotope Effect (KIE) of the enzymatic reaction in 
these studies reported that the primary isotope effect was not 
observed with [2-2H]-tryptamine and established the fact that the 
aromaticity is broken during the cyclization step, thus establishing 
cyclization as the rate-controlling step. Since the Pictet-Spengler 
reaction is principally an electrophilic aromatic substitution 
reaction, some non-enzymatic electrophilic aromatic substitution 
reactions have been reported to exhibit small KIE values,[58] 
indicating that the final deprotonation step can often be a rate-
limiting in non-enzymatic electrophilic aromatic substitution 
reactions.[57] 
2.1.2 Protein engineering of STR for improved substrate 
scope 
Protein engineering approaches are highly promising with 
respect to expanding the substrate scope, and to produce 
µXQQDWXUDO¶ QDWXUDO SURGXFWV WKDW H[KLELW QHZ RU LPSURYHG
biological activities.[59-64] Genes encoding STRs have been 
successfully isolated from Rauvolfia serpentina,[65] C. roseus,[66] 
O. pumila[67]  and O. japonica.[68]  With increasing knowledge 
about the catalytic mechanism and the residues that play 
important roles in STR-mediated biosynthesis of alkaloids, further 
efforts were devoted to broadening the substrate scope of the 
enzymes. STRs have been known to accept the analogs of their 
natural substrates tryptamine and secologanin.[69] Chen et al.[70] 
engineered an STR-Cr overexpressed in E. coli BL 21(DE3) and 
the resultant mutants were screened for their activity towards 
structural analogs of the natural substrates. These substrate 
analogs were prepared by modifications at the methyl ester (R1) 
and vinyl (R2) positions of secologanin (Figure 4). The mutant 
Asp177Ala showed a significant increase in specificity towards 
the pentynyl secologanin derivative. Another mutant, Asp177Gly, 
also moderately improved the specificity towards pentynyl 
secologanin derivative. Also, the mutant Asp177Ala in these 
studies accommodated the bulkier and more hydrophobic 
substrate analogs and the ratio of product formation for wild-type 
strictosidine to strictosidine pentinyl ester was 5.4:1.[70]    
 
Figure 4. Substrate analogs of secologanin tested for the activity towards STR-
Cr variants [70]   
It has been reported that positions 5 and 6 of tryptamine 
moiety play a crucial role in the pharmacological activities. 
However, only the tryptamine derivatives with relatively small 
substituents such as -ÀXRUR DQG -hydroxyl were principally 
accepted as substrates by STRs. Conversely, substrates with 5-
methoxy, 5-methyl or 6-methoxy exhibit much lower, or no 
transformation by native STR.[71]  To modulate the substrate 
scope of STR-Rs, Loris et al.[72]  carried out rational site-directed 
mutagenesis studies. In these studies, the bulky amino acid 
residue Val208, known to shield the steric positions of 
strictosidine, was replaced with alanine. The resultant mutant 
Val208Ala could successfully convert 5-methoxy- and 5-
methyltryptamine to the corresponding substituted strictosidine in 
the presence of secologanin. Also, the affinity of 5-
hydroxytryptamine was improved towards the mutant, as 
exhibited by the lower Km values for the Val208Ala mutant 
compared to the wild-type. Kinetic analysis also showed the 
efficient conversion of 6-methyl and 6-methoxytryptamine by 
Val208Ala mutant. It is worth emphasizing that the new STR 
mutant Val208Ala retained its enantioselectivity and thereby the 
Į-(S) configuration was retained in the new strictosidine 
analogues obtained by this protein engineering method. 
Nevertheless, the recent findings by Pressnitz et al.[73] reported 
an unexpected access to (R)-tetrahydro-ȕ-carbolines. STR-
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catalyzed Pictet-Spengler reaction of tryptamine with small-
molecular-weight aliphatic aldehydes enabled their successful 
transformation to the corresponding 1,2,3,4-tetrahydro-ȕ-
carbolines products, importantly with (R)-configuration. 
Furthermore, these studies presented the shortest and highest 
yielding biocatalytic route till date for the synthesis of natural 
alkaloid (R)-harmicine. STR-Rs-catalyzed transformation of 
commercially available methyl 4-oxobutanoate and tryptamine led 
to the formation of Pictet-Spengler product, which spontaneously 
converted to the lactam product (R)-1,2,5,6,11,11b-Hexahydro-
3H-indolizino[8,7-b]indol-3-one. Chemical reduction of this lactam 
produced (R)-harmicine with good yield of isolated product (62%) 
and excellent enantioselectivity (>98%).[73]  
Site-saturation mutagenesis strategy has also been applied 
to expand the substrate scope of STR-Cr. The sequence 
alignment studies between STRs from C. roseus and R. 
serpentina suggested that residue Val214 in the STR-Cr, 
important for substrate recognition, was equivalent to the Val208 
of STR-Rs. Accordingly, saturation mutagenesis was carried out 
at this position, and a newly developed high-throughput screening 
method was utilized to detect the activity of newly generated 
mutants. One of the most important mutations identified by the 
screening was Val214Met, which allowed the formation of 
halogenated indole alkaloids, previously unacceptable as 
substrate by wild-type STR-Cr.[74] Owing to the importance of 
halogens in improving the pharmacological properties of 
pharmaceutical compounds, the formation of halogenated indole 
alkaloids provides the important consideration of incorporating a 
halogen into all MIAs via the intermediate strictosidine.[75,76]  
These studies suggested that engineering of the indole part of the 
strictosidine molecule can be very useful strategy to generate 
large libraries of novel indole alkaloid analogs possessing novel 
biological properties.[72] Recently, a novel Pictet-Spenglerase 
function of the STR has been reported, which permitted enzymatic 
synthesis of the less frequently described piperazino [1,2-a]indole 
scaffold.[77] Owing to the wide range of biological activities of the 
compounds containing pyrazino- and piperazino[1,2-a]indole 
scaffolds, the generation of an STR-mediated synthetic method 
has great potential. 
2.1.3 Chemoenzymatic synthesis of alkaloids using STR 
The Pictet-Spengler condensation catalyzed by STRs is a 
very attractive strategy for carbon±carbon bond formation due to 
its advantages of high stereoselectivity, efficiency and mild 
reaction conditions.[78,79] Owing to the important pharmaceutical 
properties of the alkaloids synthesized by STR, research efforts 
have been devoted towards the chemo-enzymatic synthesis of 
various derivatives of the alkaloids. In the studies carried out by 
Zou et al.[80] STR-Rs was over-expressed in E. coli M15 and was 
immobilized on nickel nitrilotriacetate (Ni-NTA). This immobilized 
STR was utilized to synthesize the important alkaloid 
intermediates strictosidine and 12-aza-strictosidine, by enzymatic 
coupling of secologanin with tryptamine and 7-aza-tryptamine, 
respectively. These intermediates were further used to explore a 
possible simple chemoenzymatic synthesis of novel MIAs with 
molecular diversity and multiple chiral centers, such as nacycline, 
strictosidine lactam, tetrahydroalstonine, and their aza-analogues 
(Figure 5). While the lactams were obtained by the conversion of 
strictosidine and 12-aza-strictosidine under mild basic conditions, 
Nacycline and its 12-aza-derivative were synthesized using 
simple acidic catalyzation i.e. 2M H2SO4. To generate 
tetrahydroalstonine and its aza analogue, a one-pot 
chemoenzymatic reaction was initiateG XVLQJ ȕ-glucosidase-
catalyzed deglucosylation of strictosidine and 12-aza-strictosidine 
to form the active intermediate with ring closure. Further reduction 
of these intermediates and regiospecific electrophilic addition led 
to the generation of tetrahydroalstonine and its aza analogue.[80]  
Furthermore, these newly synthesized alkaloids were evaluated 
in vitro for their cytotoxic effects towards the human alveolar 
adenocarcinoma cell line A549, and it was concluded that newly 
incorporated nitrogen of the indole moiety renders higher 
cytotoxicity than the carbon atom at the corresponding positions 
in newly synthesized alkaloids.[80] 
 
Figure 5. STR-catalyzed chemo-enzymatic synthesis of novel MIAs [80] 
Further studies by Bernhardt et al demonstrated the first 
example of aldehyde substrate promiscuity of STR from 
Ophiorrhiza pumila (STR-Op) for the Pictet±Spengler 
condensation of a range of simple achiral aldehydes and 
substituted tryptamines to form highly enantioselective (ee >98%) 
tetrahydro-ȕ-carbolines.[81] These studies demonstrated that 
STR-Op preferred the aldehyde substrates, however, 
unsubstituted at the alpha position. Furthermore, the absolute 
configuration of the enzymatic products was 3-(S), which was the 
same as to that of the natural substrate secologanin. It is 
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noteworthy that the enantioselectivity of the product formed by the 
reaction between tryptamine and secologanin was preserved with 
achiral aldehydes substrates, implying that the enantioselectivity 
of the product formed does not rely on the chirality of the 
secologanin substrate.[81] 
Most recently, Cai et al.[78] reported the enantioselective 
synthesis of three N-substituted (S)-3,14,18,19-
tetrahydroangustine (THA) derivatives.[78] Previous studies have 
established the camptothecin and evodiamines as potential 
Topoisomerase I inhibitors.[82,83] As the structural arrangement of 
THA derivatives was similar to camptothecin and the evodiamines, 
it was postulated that the N-acylated THA derivatives designed in 
this study would also exhibit potential antitumor activity. Also, to 
evaluate the differential effect of different configurations, 3-(S)-
THAs were prepared by an STR-mediated chemo-enzymatic 
approach (Figure 6), and their corresponding (R)-enantiomers 
were chemically synthesized using vincosamide (Figure 6; upper 
panel). The preliminary inhibitory screening studies suggested 
that the 3-(S)-THA derivatives were about 3-fold more potent for 
both in vitro HepG2 cytotoxicity and Top1 inhibition, compared to 
their corresponding (R)-enantiomers.  
 
Figure 6. STR-catalyzed chemo-enzymatic synthesis of N-acylated THA 
derivatives [78] 
MD simulations of the enantiomers with topoisomerase 1 
(PDB ID: 1k4t) suggested that (R)-enantiomers were pushed out 
of the binding pocket of Top1, while in the case of the 
corresponding S-HQDQWLRPHUDQLQGXFHGILWZDVREVHUYHGZLWKʌ-
stacking interactions that remained strong throughout the 
simulation. Furthermore, the lack of potency of the (R)-
enantiomers was correlated to the out-of plane angle between the 
indole ring and the rest of the ring system. In contrast, the (S)-
enantiomer was found to be much more planar, facing more 
empty room in the pocket, thereby allowing for free substitution of 
the indole nitrogen in (S)-enantiomers. This extended flexibility 
was also proposed as a plausible reason for the higher cytotoxic 
effects of the (S)-enantiomers and their substituents.[78] 
Fischereder et al. recently demonstrated the formation of 
(S)-strictosidine derivatives possessing an additional stereogenic 
center at C3 of the tetrahydro-ȕ-carboline core using a biocatalytic 
FDVFDGH LQYROYLQJ Ȧ-TA and STR.[84] In these studies, a 
stereoselective amination of prochiral ketones was performed 
using Ȧ-7$ WR JHQHUDWH Į-methyltryptamine derivatives. In the 
second step, a Pictet Ѹ 6SHQJOHU FRQGHQVDWLRQ RI Į-
methyltryptamine derivatives with secologanin was catalyzed by 
STR to form optically pure C3-methyl-substituted strictosidine 
derivatives. Furthermore ERWK WKH HQDQWLRPHUV RI Į-
methyltryptamine derivatives could be synthesized using 
VWHUHRFRPSOHPHQWDU\ Ȧ-TAs, which ultimately allowed the 
preparation of both the epimers of C3-methyl-substituted 
strictosidine derivatives.[84] (Figure 7).  
2.2 Norcoclaurine synthase 
Norcoclaurine synthase (NCS; E.C. 4.2.1.78) catalyzes the 
condensation of dopamine and 4-hydroxyphenylacetaldehyde (4-
HPAA) through the formation of a C±C bond to form (S)-
norcoclaurine. NCS plays a rate-limiting role in the biosynthesis 
of benzylisoquinoline alkaloids in plants, as norcoclaurine serves 
as a precursor for over 5,000 benzylisoquinoline alkaloids 
(BIQs).[85,86] (Figure 8). Thus, the role of Norcoclaurine synthase 
in the biosynthesis of benzylisoquinoline alkaloids is comparable 
to that played by strictosidine synthase in the biosynthesis of 
MIAs.[86] Owing to the diverse array of BIQs, these alkaloids 
exhibit a broad range of pharmacological activities, for example, 
codeine and morphine are used as analgesic, while papaverine is 
used as a muscle relaxant.[87] (Figure 8).  
NCS was originally known as norlaudanosoline synthase 
because of its ability to convert dopamine and 3,4-
dihydroxyphenylacetaldehyde (3,4-DHPAA) to (S)-
norlaudanosoline.[88] As NCS accepted both the substrates i.e. 4-
HPAA or 3,4-DHPAA, it was wrongly concluded that (S)-
norlaudanosoline serves as a common pathway intermediate in 
the biosynthesis of benzylisoquinoline alkaloids. However, further 
detailed studies established that only (S)-norcoclaurine was found 
in plants.[88-90] 
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Figure 7. %LRFDWDO\WLF FDVFDGH HPSOR\LQJ Ȧ-TA and STR for the chemo-enzymatic synthesis of C3-methyl-substituted enantiopure strictosidine derivatives 
[Reprinted with the permission from Fischereder et al.,[84]  Copyright 2016, American Chemical Society] 
 
Figure 8. Role of (S)-norcoclaurine as a central precursor in the synthesis of diverse range of pharmacologically important benzylisoquinoline alkaloids 
2.2.1 Structure, and mechanistic of NCS-catalyzed reaction 
The presence of NCS was first detected in plants belonging to 
three families: the Berberidaceae, Papaveraceae, and 
Ranunculaceae. In early 1980s, Zenk and co-workers reported 
the presence of NCS in the cell material of ten plant genera that 
were unique in producing BIQ-type alkaloids. Furthermore, it was 
detected that phenylpyruvate and its derivatives, such as 4-
hydroxy and 2,4-dihydroxy, do not serve as substrates for 
NCS.[42,88-92] Further studies by Facchini et al. in the next decade 
gained deeper insights into NCS.[93-95] In their studies, Samanani 
et al. purified NCS 1590-fold from the cell suspension cultures of 
the medicinal plant Thalictrum flavum (Meadowrue), belonging to 
the family Ranunculaceae and known to accumulate the BIQ 
alkaloids, such as berberine and magnoflorine.[94] The purified 
NCS was reported to exist in four isoforms, two major and two 
minor charge isoforms that showed pI values of 5.5 and 6.2, 
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respectively.[94] It is notable that kinetic analysis of the product 
inhibition exhibited uncompetitive binding pattern for 4-HPAA and 
noncompetitive binding for dopamine, implying that aldehyde 
substrate in NCS-mediated catalysis binds to the enzyme before 
its amine counterpart.[94] 
Further research by Samanani et al.[95] allowed them to 
isolate a full-length cDNA, containing a 630-bp open-reading 
frame, from the cell culture library of T. flavum. However, the 
expression of this full-length ORF resulted in very low 
heterologous expression of the recombinant NCS. Nevertheless, 
the construct encoding truncation of the first 19 N-terminal amino 
acids was established later, permitting the production of C-
terminal His-tagged polypeptides in E. coli.[95] Further optimization 
of the expression system in E. coli allowed the production of 15 
mg of homogenous and active protein per liter of bacterial 
culture.[93]  
Subsequently, Minami et al. carried out the functional 
analysis of an NCS as well as a pathogenesis-related 
homologous protein (PR-10) from Coptis japonica.[96] These two 
enzymes are completely dissimilar to one another; however, both 
exhibited NCS activity. Substrate specificity studies of NCS from 
C. japonica [NCS-Cj] suggested that among the various amine 
substrates, such as dopamine, tyramine, tryptamine, 
noradrenaline, 2-phenylethylamine, and 3-hydroxy-4-
methoxyphenethylamine, with 4-HPAA as an aldehyde donor, 
only dopamine was accepted as a substrate and produced the 
condensation product norcoclaurine.[96] Nevertheless, various 
aldehydes and carboxylic acids were accepted as substrates, and 
produced condensation products when reacted with dopamine as 
an amine substrate. For example, the reactions of dopamine with 
phenylacetaldehyde, 3,4-dihydroxyphenylacetaldehyde, and 4-
HPAA produced 1-benzyl-6,7-dihydroxy-1,2,3,4-
tetrahydroisoquinoline, norlaudanosoline, and norcoclaurine, 
respectively.[96]  
The aim of determining the NMR solution structure of NCS 
from T. flavum [NCS-Tf] served as a vehicle to optimize the 
overexpression, and establish the purification protocol, yielding 
pure and isotopically labelled protein in sufficient amounts. In 
studies performed by Berkner et al., two heterologous E. coli 
expression systems had been developed, resulting in truncated 
His-tagged NCS.[97] The two- and three-dimensional NMR studies 
and CD spectroscopic studies performed by Berkner et al. 
indicated the high similarity of NCS to a birch pollen allergenic 
protein, Bet v 1.[98] In these studies, 86% of the amino acid 
sequence of the truncated NCS was assigned and the homology 
model was built using the crystal structure of Bet v1 as a template. 
Chemical shift index (CSI) analysis suggested that not only the 
secondary structure content of NCS but also the distribution of 
secondary structure elements was similar to that of Betv1. The 
NCS has been reported to consist of seven-stranded antiparallel 
ȕ-sheets wrapped around a long C-WHUPLQDOKHOL[ ĮDQG WZR
VPDOOHU Į-KHOLFDO VHJPHQWV Į DQG Į $OVR D VHULHV RI
hydrophobic residues and a polar patch located at the entrance 
of the cavity forms an accessible cleft in each monomer of 
NCS.[93,99] The homology modelling studies, along with CSI and 
NMR titration experiments, suggested that while Phe71 can form 
hydrophobic interactions with the aromatic ring of the dopamine 
substrate, Met155 was associated with the aliphatic part.[98] 
Structural studies of NCS were extended by crystallization 
and X-ray analysis[100,101] (Figure 9A). These studies suggested 
that the geometry of the NCS active site is dominated by four 
important amino acid residues; three strong proton exchangers, 
Lys122, Asp141, and Glu110, and one hydrogen bonding donor, 
Tyr108 (Figure 9B).  
 
Figure 9. A) Structure of NCS from T. flavum [PDI ID: 2VNE]; and B) Interaction 
of catalytic residues of NCS with dopamine and 4-HPA substrates [100].  
To further establish the role of active side residues, this group also 
generated the site-specific mutants of the catalytically competent 
amino acid residues.[100] A Lys122Ala mutant was found to be 
completely inactive, implying that Lys122 is the key catalytic 
residue. In contrast, replacement of Tyr108 and Glu110 with Phe 
or Ala, respectively, resulted in diminished NCS activity. It is 
notable that the catalytic mechanism was proposed based on the 
arrangement of the catalytic residues and NCS was proposed to 
adopt the different mechanism to catalyze the Pictet-Spengler 
cyclization compared to that of STR.[99,100] The mechanism 
proposed by these studies concluded that the aldehyde substrate 
(4-HPAA) binds to the NCS prior to dopamine (thH µ+3$$-¿UVW¶
mechanism). Subsequently, an alternative mechanism was 
proposed using computational techniques, wherein dopamine 
ELQGVWRWKH1&6SULRUWRWKHDOGHK\GHVXEVWUDWHWKHµGRSDPLQH-
¿UVW¶PHFKDQLVP[102] Recently, Lichman et al.[103] compared the 
WZR SURSRVHG PHFKDQLVPV µWKH +3$$-¿UVW PHFKDQLVP¶ ZDV
studied using holo-X-UD\FU\VWDOVWUXFWXUHDQGµWKHGRSDPLQH-¿UVW
PHFKDQLVP¶ XVLQJ FRPSXWDWLRQDO GRFNLQJ VWXGLHV ,Q WKHVH
VWXGLHVµWKH+3$$-¿UVWPHFKDQLVP¶ZDVSURSRVHGEDVHGRQWKH
arrangement of the substrates in subunit B.[99,100,103] The holo-
crystal structure in these studies failed to explain the reactivity of 
NCS towards various aldehyde substrates. Also, the 
simultaneous incorporation of large aldehydes such as citronellal 
and amine substrate dopamine in the proposed stacked formation 
with NCS active site could not be explained.  
2Q WKH RWKHU KDQG µWKH µGRSDPLQH-¿UVW¶ PHFKDQLVP¶ ZDV
validated using the docking results of the substitutions at selected 
amino acid, Tyr108, Glu110, Lys122, and Asp141. The 
replacement of Lys122 with Leucine resulted in the loss of NCS 
activity towards 4-HPAA, corroborating the previous results which 
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suggested that Lys122 plays a crucial role in the rate-limiting 
cyclization step. Also, the role of Asp141 was established in the 
general electrostatic stabilization. Furthermore, the dual role of 
Tyr108, contributing to the electrostatic properties of the active 
site, but also in defining the shape of the cavity entrance was 
established.[103] Most recently, the studies by Lichman et al.[104] 
presented new high-resolution X-ray crystallography data 
describing NCS-Tf bound to a mechanism-inspired ligand, which 
VXSSRUWHGWKHNH\IHDWXUHVRIµWKHGRSDPLQH-¿UVWPHFKDQLVP¶ 
Recent years have achieved seen significant advances in 
understanding of enzyme structure and the mechanism of NCS-
mediated cyclization of amine and aldehyde substrates. This 
improved understanding of NCS mechanism will prove useful in 
the rational engineering approaches to extend the substrate 
scope for the synthesis of novel alkaloids possessing the 
µSULYLOHJHGVFDIIROG¶, THIQ, and thereby benzylisoquinolines.[105] 
2.2.2 Extended substrate scope and chemo-enzymatic 
synthesis of benzylisoquinoline alkaloids using NCS 
As numerous biologically active substances that act as 
important pharmaceutical drugs include the THIQ scaffold, they 
are considered as important secondary metabolites.[106] Also, the 
product of the reaction catalyzed by NCS, i.e (S)-norcoclaurine, is 
a potent alternative to dobutamine, the besWFXUUHQWȕ-adrenergic 
drug. However, the clinical development of (S)-norcoclaurine is 
limited by its low availability in Nature and further by the expensive 
stereoselective methods required for synthesis. Although the 
catalytic mechanism of NCS-mediated condensation has been 
established, the strategy for the multigram synthesis of (S)-
norcoclaurine was unavailable until recently. Also, the previous 
reactions for the synthesis of (S)-norcoclaurine have been 
reported to suffer from insufficient yields and higher production of 
byproducts. In 2010, Bonamore et al.[107] reported the first 
successful example of a green, enzymatic synthesis of the key 
precursor of benzylisoquinoline alkaloids (S)-norcoclaurine.  In 
those studies, (S)-norcoclaurine was synthesized from the cheap 
tyrosine and dopamine substrates in a one-pot, two-step process 
employing NCS-Tf. As aldehyde substrate 4-HPAA is highly 
unstable in aqueous solution and commercially unavailable, it was 
synthesized by the oxidative decarboxylation of tyrosine in the 
presence of an equimolar amount of hypochlorite, and was 
immediately used in the enzymatic reaction.[107] The subsequent 
addition of dopamine substrate and the use of multipurpose 
activated charcoal afforded the extraction of (S)-norcoclaurine 
with high yield (80%) with excellent enantioselectivity (93% ee) 
(Figure 10).  
 
Figure 10. One-pot chemo-enzymatic synthesis of (S)-norcoclaurine from 
tyrosine and dopamine [Adapted with permission from Bonamore et al.[107] 
Copyright 2010, The Royal Society of Chemistry] 
To develop a biocatalytic strategy for the synthesis of 
various THIQ derivatives, Ruff at al.[108] described the substrate 
scope of NCS-Tf. NCS-Tf was found to successfully catalyze the 
reaction between normal amine substrate dopamine, and various 
aldehyde substrates, such as acetaldehydes containing more 
WKDQ  FDUERQ DWRPV DQG WKRVH XQVXEVWLWXWHG DW WKH Į-position 
(Figure 11). Also, aromatic acetaldehydes were efficiently 
converted to their respective products with higher rates compared 
to the aliphatic compounds. This substrate flexibility exhibited by 
NCS-Tf suggested an efficient enzymatic method for the 
synthesis of a diverse array of THIQ derivatives, such as 1-(ortho-, 
meta- and para-substituted benzyl)- THIQs.[108] 
 
Figure 11. Aldehyde substrate specificity of NCS-Tf [108] (% conversion to 
corresponding products is given in parenthesis)  
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Several other 1-substituted-1,2,3,4-THIQs were also 
stereoselectively synthesized using NCS-Cj.[109] NCS-Cj proved 
to be a promising biocatalyst that could synthesize 6,7-dihydroxy-
1-phenethyl-1,2,3,4-THIQ and 6,7-dihydroxy- 1-propyl-1,2,3,4-
THIQ with higher molar yields (86.0 and 99.6%, respectively) with 
excellent enantioselectivities of 95.3 and 98.0% ee, 
respectively.[109] 
Recently, Maresh et al. reported the generation of 
halogenated 4-HPAA and norcoclaurine from amino acids in 
aqueous media, avoiding the use of toxic reagents. Furthermore, 
these halogenated aldehyde substrates could be utilized for the 
enzymatic synthesis of enantioselective (S)-norcoclaurine 
analogs.[110] It is worth mentioning that these studies extensively 
expanded the substrate scope of NCS and proposed for the first 
time that halogenated substituents of the natural phenol substrate 
can be accepted by NCS (Figure 12). 
 
Figure 12. The stereospecific chemo-enzymatic synthesis of halogenated 
derivatives of (S)-norcoclaurine [110] 
Lichman et al. in 2015 reported a one-pot two-enzyme 
µWULDQJXODU¶ cascade for the synthesis of (S)-norlaudanosoline, an 
endogenous BIA precursor for morphine, using the enzymes 
transaminase and NCS. Furthermore, the subsequent addition of 
formaldehyde triggered the second Pictet-Spengler reaction to 
form (S)-10,11-dihyroxy tetrahydroprotoberberine[111] (Figure 13). 
In a preparative scale synthesis, dopamine substrate was 
converted to (S)-norlaudanosoline with 86% conversion (62% 
isolated yield; >95% ee). Subsequently, (S)-10,11-dihyroxy 
tetrahydroprotoberberine was formed with 47% conversion (42% 
isolated yield; >95% ee).[111] 
Recently, Bonamore et al.[112] developed a fully enzymatic 
strategy for the synthesis of substituted THIQs. The first step 
consisted of the transformation of a variety of aliphatic and 
aromatic amines to the corresponding aldehydes by diamine 
oxidase enzyme from Lathyrus cicera. In the subsequent step, 
aldehyde obtained in the first step was mixed with the dopamine 
to yield (S)-configured THIQs using NCS-Tf.  Notably, excellent 
conversion (95-98%), yields (72-83%) and enantiopurity (> 99% 
ee) could be achieved for all the products formed by this strategy 
(Figure 14). 
 
Figure 13. 7KHELRFDWDO\WLFµWULDQJXODU¶FDVFDGHHPSOR\LQJȦ-TA-Cv and NCS-
Tf for the synthesis of (S)-norlaudanosoline [Adapted with permission from 
Lichman et al.,[111] Copyright 2015, The Royal Society of Chemistry] 
 
Figure 14. A) Biocatalytic cascade for the stereoselective synthesis of 1-
substituted-(S)-THIQs using LCAO and NCS-Tf and B) Amine substrates tested 
and the synthesis of corresponding THIQ products [112] 
The applicability of NCS was further demonstrated by 
Erdmann et al.[113] in the enzymatic and chemoenzymatic 
synthesis of 1,3,4-trisubstituted THIQs with three chiral centers 
using the cascade of three reactions. In the first reaction, 
carboligation of 3-hydroxybenzaldehyde and pyruvate was 
carried out using carboligase to generate (R)-1-hydroxy-1-(3-
hydroxyphenyl)propan-2-one. In the subsequent reaction, 2-
amino-1-(3-hydroxyphenyl) propan-1-ol was generated using 
transaminase-mediated biotransformation using IPA as an amine 
donor. Finally, the product of the previous reaction underwent 
NCS-mediated Pictet-Spengler condensation with the carbonyl 
co-substrate phenylacetaldehyde to generate THIQ product 
(1S,3S,4R)-1-benzyl-3-methyl-1,2,3,4-tetrahydroisoquinoline-
4,6-diol with an excellent yield of 92% (Figure 15A). It is notable 
that the chemical cyclization catalyzed by phosphate gave 
opposite stereoselectivity in the synthesis of C1-substituted 
THIQs (Figure 15B). Thus, enzymatic and chemo-enzymatic 
methods provided access to both orientations of the THIQ 
substituents.[113] 
 
  
10.1002/cctc.201801130
Ac
ce
pt
ed
 M
an
us
cr
ip
t
ChemCatChem
This article is protected by copyright. All rights reserved.
REVIEW          
 
 
 
 
 
 
Figure 15. A) Enzymatic synthesis of 1-benzyl-7+,4VHPSOR\LQJWKHFDVFDGHRIFDUEROLJDVHȦ-Transaminase and NCS; and B) Chemo-enzymatic synthesis of 1-
benzyl-THIQs [Reprinted with permission from Erdmann et al.,[113] Copyright 2017, John Wiley and Sons] 
Although NCSs exhibit wide tolerance for various aldehyde 
substrates, a strategy for the stereoselective Pictet-Spengler 
condensation of unactivated ketones was unavailable until very 
recently. Lichman et al.[114] have presented the first example of 
NCS-catalyzed Pictet-Spengler condensation with unactivated 
ketones (Figure 16). In their studies, wild type NCS-Tf was utilized 
for the condensation of dopamine and 4-hydroxyphenylacetone 
LQWRD¶-disubstituted THIQ. Acceptance of a ketone substrate 
4-hydroxyphenylacetone served as a starting point to further 
investigate the extended scope of ketone substrates using 
variants of WT-NCS-Tf. Along with 4-hydroxyphenylacetone, 
several other ketones such as phenylacetone, cyclohexanone, 
and 4-methyl-, 4-tert-butyl- and 4-phenyl- substituted 
cyclohexanones were accepted as substrates and converted to 
their corresponding products. Notably, the mutation of the amino 
acid residue Ala79 most significantly affected the acceptance of 
ketone substrates. For instances, the product formation in 
Ala79Ile was twice as that of WT for the methyl ketone substrates. 
Another substitution, Ala79Phe, improved the conversion for all 
the cyclohexanone substituent substrates. Furthermore, various 
chiral and spiro-¶-disubstituted THIQs were biocatalytically 
synthesized using NCS-Tf variants (Figure 16). The extension of 
the substrate scope of NCS was followed by the most recent 
studies by Lechner et al.,[115] who reported the extension of the 
panel of Pictet-Spenglerase NCS and their immobilization for the 
biocatalytic generation of isoquinoline products.[115] The library of 
nine various NCSs was initially tested for their ability to condense 
the dopamine and 4-HPAA substrate using lyophilized whole cells 
as biocatalysts. Furthermore, the most active enzyme, NCS from 
Papaver bracteatum (NCS-Pb) was purified and immobilized on 
10 different carriers. The immobilized catalyst was used in the 
flow-based system, wherein it resulted in high optical purity and 
significant product concentrations.  
 
Figure 16. %LRFDWDO\WLF V\QWKHVLV RI ¶-disubstituted THIQs using NCS-Tf 
variants [114] 
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The last few years have witnessed the extensive utilization 
of Pictet-Spenglerase enzymes for the stereoselective synthesis 
of a diverse array of alkaloids. Significant achievements have 
been achieved in the understanding of the catalytic mechanisms 
and substrate scope of the enzymes carrying Pictet-Spengler 
condensation. To this end, the most recent advance in NCS-
mediated synthesis of THIQs is the detection of variants accepting 
substituted ketones as substrates. Furthermore, recent years 
have seen a trend of rational engineering of metabolic pathways 
in microbial species for the synthesis of alkaloids of 
pharmaceutical importance.[4,7,9,114,116-118] Recent advances in the 
improvement of substrate scope of the Pictet-Spenglerase 
enzymes can form the foundation of biosynthetic pathways in the 
microbial systems for the generation of novel alkaloids with 
improved and novel pharmaceutical activities. Additionally, a 
handful of new enzymes carrying the Pictet-Spengler reaction 
such as salsolinol synthase,[119] McbB from Marinactinospora 
thermotolerans,[120] deacetylisoipecoside synthase, and 
deacetylipecoside synthase,[121] two novel NCSs from Argemone 
mexicana (AmNCS1, AmNCS2) and one new NCS 
from Corydalis saxicola[115] have recently been identified. The 
development in the understanding of these enzymes will further 
enrich the biocatalytic synthesis of a myriad of alkaloids with 
diverse pharmaceutical functions.[42,122-126] 
3. Berberine bridge enzyme (BBE) 
The berberine bridge enzyme (BBE; E.C. 1.21.3.3), a flavin-
dependent oxidase, catalyzes the oxidative cyclization of THIQ 
(S)-reticuline to (S)-scoulerine by the formation of intramolecular 
C-C-bond, the so-called berberine-bridge.[127] (S)-scoulerine is the 
branch point intermediate in the biosynthetic pathway that leads 
to the formation of protoberberine, protobine and 
benzophenanthridine alkaloids.[128,129] These alkaloids and their 
substituents have been demonstrated to possess 
antimicrobial,[130] antiprotozoal,[131] antibacterial,[132]  antitumor,[133-
137]
 and anti-HIV properties,[138]  along with several other 
pharmacological properties, such as antihypertensive, 
antiarrhythmic, and anti-diabetic.[139]   Berberine has also been 
shown to possess a cholesterol-lowering property, thereby 
exerting a protective role in atherosclerosis.[140] Furthermore, 
berberines are known to possess central nervous system 
activities and might act as an herbal antidepressant.[127] Most 
recently, berberine derivatives have been reported to exhibit anti-
influenza activity through the blocking of neuraminidase [141,142] 
(Figure 17). 
 
Figure 17. A natural reaction catalyzed by BBE and the role of (S)-scoulerine in 
the synthesis of pharmaceutically important alkaloids 
Though BBE was first isolated from Berberis beaniana in 
1985,[143] its activity was first detected a decade earlier in 1975 
from Macleaya microcarpa.[144] Steffen et al.[143] attempted to 
develop a convenient assay method, and reported the presence 
of active BBE in 66 differentiated plants and cell suspension 
cultures, mainly from the Papaveraceae and Fumariaceae 
families. 
In light of the mechanism of BBE, it has been established 
that the ring closure in the conversion of (S)-reticuline to (S)-
scoulerine is carried out by the intramolecular C-C bond coupling 
between the N-PHWK\O JURXS DQG WKH ¶-carbon of the benzyl 
moiety of (S)-reticuline.[145] However, the characterization of BBE 
was previously limited owing to the quantities of purified enzyme 
available.  
Kutchan and Dittrich[146] isolated the cDNA encoding the 
BBE followed by its overexpression in insect cell culture. In their 
studies, it was demonstrated that in the heterologously expressed 
enzyme, the FAD cofactor is covalently linked to a His104 residue 
YLD LWV Į-position.[146] Also, it was proposed that the reaction 
mechanism of BBE-mediated cyclization of (S)-reticuline to (S)-
scoulerine proceeds in two steps. The first step consists of the 
formation of the methylene iminium ion. The second step, ionic 
ring closure forming the berberine bridge of (S)-scoulerine, is 
stereospecific in nature.[146] The following section highlights the 
advancements in the heterologous expression, characterization 
and catalytic mechanism of BBE-mediated conversion of (S)-
reticuline to (S)-scoulerine. 
3.1 Heterologous expression of BBE  
With the aim of gaining deeper insights into the structure 
and catalytic mechanism, various expression systems have been 
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developed to heterologously express the BBE.[147] Kutchan et 
al.[148]  expressed a gene encoding BBE from California poppy (E. 
californica) in Spodoptera frugiperda Sf9 cells using the 
baculovirus-based expression system. A maximum production of 
4 mg of purified protein could be achieved using this expression 
system that allowed basic characterization of substrate specificity. 
Similar to BBE from California poppy, three unique genomic 
clones (bbel, bbe2, and bbe3) were isolated from opium 
poppy.[149]  These studies reported that not all BBE homologs in 
Opium poppy are functional, as only bbel was expressed and 
encoded a functional BBE protein.[149] However, the heterologous 
expression of BBE in bacterial cells or in S. cerevisiae led to an 
insoluble protein or to very small amounts of soluble and active 
enzyme.[150] The high expression of BBE was limited by the 
presence of N-terminal signal peptide and vacuolar sorting 
determinan.[150,151] Also, an active form of BBE was N-
glycosylated and requires covalently bound FAD.  
Subsequently, a high-level expression system for BBE from 
California poppy was developed in the methylotrophic yeast 
Pichia pastoris employing the secretory pathway of the host.[147] 
120 mg of BBE per liter of fermentation broth were obtained in 
these studies using a two-step chromatographic purification 
protocol. This quantity of BBE achieved was 30 times more than 
that previously reported for the enzyme isolated from insect cell 
culture.[148]  
3.2 Crystal structure, and mechanism of BBE-catalyzed 
reaction 
The N-terminal amino acid sequencing and mass 
spectrometric analysis of the isolated flavin-containing peptide 
provided evidence for the bi-covalently attached FAD cofactor 
and also covalent linkage between the 6-position and the thiol 
group of a cysteine residue (Cys-166) in BBE.[147] The sequence 
similarity of BBE with glucooligosaccharide oxidase (GOOX) and 
1-tetrahydrocannabinolic acid synthase implied that BBE belongs 
to a novel group of flavoproteins containing a bi-covalently 
attached flavin cofactor. 
The importance and role of covalent linkages in BBE was 
further addressed by Winkler et al.[152] Amino acid residues 
involved in the bi-covalent attachment of the cofactor to BBE, i.e. 
His104 and Cys166 were mutated. The replacement of Cys166 
with alanine reduced the turnover rate of BBE to 6% compared to 
that of wild-type. The measurement of redox potentials in these 
studies suggested that 6-S-cysteinyl linkage is a critical 
determinant of the rate of flavin reduction, and ultimately of the 
oxidation of (S)-reticuline to (S)-scoulerine. Furthermore, the 
removal of 6-S-cysteinyl linkage obtained a similar redox potential 
to that of other flavoproteins, implying that the deviations of kinetic 
properties in BBE are due to the FAD-6-S-cysteinyl bond. It is 
worth emphasizing that the results of rapid reaction stopped-flow 
experiments supported a hydride transfer mechanism from the N-
methyl group of the substrate to the flavin cofactor.[152]   
Since 1995, when Kutchan and Dittrich proposed a two-step 
process for the formation of berberine bridge that initiates with the 
oxidation of the N-methyl group to the corresponding iminium ion, 
followed by an ionic ring closure initiated by the deprotonated 
&މ2+ JURXS RI WKH EHQ]\O PRLHW\[146] various studies have 
suggested that the mechanism of BBE-mediated reactions is 
similar to those of other flavin-dependent enzymes.[153,154] 
Subsequent research efforts by Winkler et al.[155] elucidated 
the three-dimensional X-ray crystal structure of the BBE from E. 
californica in complex with the natural substrate (S)-reticuline, 
which provided the ultimate proof for the bi-covalent binding of the 
ÀDYLQ FRIDFWRU[155] (Figure 18). The BBE enzyme structure was 
reported to consist of two domains; a FAD binding domain, and 
DQ Įȕ GRPDLQ ZLWK D VHYHQ-VWUDQGHG DQWLSDUDOOHO ȕ-sheet that 
forms a substrate binding domain.[155] The substrate, (S)-reticuline, 
is sandwiched between the flavin cofactor and amino acid 
UHVLGXHV H[WHQGLQJ IURP WKH ȕ-sheet of the central domain, 
FRQVLVWLQJRIȕ-sheet.[129,155] 
 
Figure 18. A) Crystal structure of BBE in complex with (S)-reticuline [PDB ID: 
3D2D]; B) Interactions between (S)-reticuline substrate and active site amino 
acids [155]  
For better understanding of the formation of the Berberine Bridge, 
these studies involved the site-directional mutational analysis of 
the active site amino acid residues Glu417, Tyr106, and His459 
with Gln, Phe, and Ala, respectively. Eventually, the concerted 
mechanism for the formation of the berberine bridge has been 
proposed, wherein Glu417 has important mechanistic 
implications by acting as a catalytic base. This catalytic base 
GHSURWRQDWHVWKH&¶K\GUR[\JURXSRIWKHVXEVWUDWHDQGWKHUHE\
LQFUHDVHV WKH QXFOHRSKLOLFLW\ RI WKH &¶ DWRP ZKLFK IXUWKHU
facilitates the SN2-nucleophilic attack on the N-methyl group of 
the substrate. Consequently, the C-C methylene bridge is formed, 
and hydride is concomitantly transferred to the flavin 
cofactor[129,155] (Figure 19). Recently, a series of substrate 
deuterium and solvent kinetic isotope effect studies provided 
additional evidence in support of the concerted mechanism of 
BBE-catalyzed formation of the berberine bridge.[156] 
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Figure 19. A concerted mechanism of BBE-catalyzed oxidative cyclization of 
(S)-reticuline [Reprinted with permission from Winkler et al.,[155] Copyright 2008, 
Springer Nature] 
3.3 Substrate scope of BBE 
The studies by Kutchan and Dittrich,[146] which expressed 
the BBE in insect cell culture, also demonstrated the substrate 
scope of BBE. Among the 19 tetrahydrobenzylisoquinolines, BBE 
catalyzed the formation of berberine bridge in five compounds, i.e. 
(S)-reticuline, (S)-protosinomenine, (R,S)-crassifoline, (R,S)-6-O-
methyllaudanosoline, and (R,S)-laudanosoline, leading to 
conversion to corresponding protoberberines. Though the 
conversion rates for racemic forms of these substrates were low, 
it should be noted that enzyme is specific only for the S-epimer. 
Among the tested tetrahydroprotoberberine alkaloids, a double 
bond between the nitrogen and C8 was introduced in (S)-
coreximine and (S)-norsteponine. It was concluded that the 
presence of the (S)-configuration at C1 and the substitution of the 
aromatic carbon ortho- WR&މRIWKHULQJFORVXUHZLWKDK\GUR[\O
group were structural requirements for the formation of berberine 
bridge in N-methyltetrahydrobenzylisoquinoline. Moreover, the 
substitution pattern of the aromatic ring moiety of the isoquinoline 
nucleus did not affect the formation of the berberine bridge. Also, 
the hydroxyl group of benzyl moiety was presumed to play a 
crucial role in the bridge formation, as the enzyme was inactive 
towards the substrates lacking the hydroxyl group (Figure 20).  
 
Figure 20. Substrate scope of BBE [146] 
3.4 Extension of substrate scope and BBE-catalyzed 
chemo-enzymatic synthesis of alkaloids 
As the berberine family of alkaloids consists of many 
important pharmaceutically important modalities, various 
chemical and enzymatic methods have been developed for the 
synthesis of novel unnatural products. Despite the advances in 
various chemical methods, such as metal-catalyzed asymmetric 
hydrogenation,[157] intramolecular allylic amination[158] and metal- 
or organo-catalyzed asymmetric alkylation reactions,[159] 
enantiopure products (>99% ee) were scarcely produced. 
Furthermore, chemical methods also have been reported to be 
time consuming and with low productivity and thereby yielding low 
product level.[145] Also, the isolation of these alkaloids from their 
natural source is very time consuming.[28,129] 
Schrittwieser et al.[160] initiated studies to check the 
promiscuity of the BBE and synthesized unnatural substrates with 
a yield of 40% in a 5-step synthesis process. These studies 
suggested that four non-natural racemic THIQ substrates, lacking 
WKHPHWKR[\JURXSDW¶-position of reticuline and possessing a 
methoxy group in position 7 of the benzylisoquinoline backbone, 
could be accepted by BBE[160] (Figure 21). Furthermore, it was 
also demonstrated that these substrates could be synthesized on 
a higher scale, and 1 g/L of BBE successfully turned over all the 
substrates at concentrations of 20 g/L. This large quantity of 
substrates could be accommodated by employing 0.05 g/L 
catalase, to prevent the inhibitory effect of hydrogen peroxide, and 
by performing the reaction in the presence of organic co-solvents 
to improve the solubility of the substrates. Among the various 
organic solvents tested, the BBE was stable in the biphasic 
reaction employing toluene, benzene, and diphenyl ether. 
Furthermore, it was found that while the (R)-enantiomers were 
inactive, only (S)-enantiomers of these non-natural THIQs could 
be accepted as substrates by BBE, implying the high 
stereoselectivity of the enzyme. BBE catalyzed the kinetic 
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resolution of all the racemic substrates to yield optically pure (S)-
products [>97% ee], with a minor side product wherein the C-C 
ERQG ZDV IRUPHG XVLQJ WKH ¶-FDUERQ DWRP LQVWHDG RI WKH ¶-
carbon atom[160] (Figure 21). 
 
Figure 21. Biocatalytic enantioselective oxidation of non-natural THIQs 
catalyzed by BBE and the preparative scale (500 mg) kinetic resolution of 
racemic substrates [160] 
Nevertheless, considering the diverse pharmacological 
profile of the (S)-scoulerine derivatives, newly synthesized non-
natural THIQ products served as a vehicle for the discovery of 
new pharmaceutically important alkaloids. The chemoenzymatic 
synthesis of non-natural THIQ products was further optimized for 
the reaction conditions such as pH, temperature and solvents.[161]  
Schrittwieser et al.[162] further extended the 
chemoenzymatic synthesis of berberine and benzylisoquinoline 
derivatives. In their studies, racemic 1-benzyl-1,2,3,4-THIQs were 
synthesized using two distinct pathways, i.e. Bischler Napieralski 
cyclization, or by alkylation of Boc-protected 
tetrahydroisoquinoline. An enantioselective oxidative C-C 
coupling, mediated by BBE, generated enantiopure (R)-
benzylisoquinoline and (S)-berbine alkaloids with excellent 
enantioselectivity [>97% ee; E > 200] and yields ranging from 22-
50% (Maximum theoretical yield-50%)[162] (Figure 22). It was 
notable that the synthetic route demonstrated by Schrittwieser 
achieved the asymmetric synthesis of (S)-scoulerine for the first 
time on a preparative scale of 0.5 g, wherein 230 mg of 
enantiomerically pure (S)-scoulerine was yielded by 9 linear 
steps.[162] 
 
Figure 22. BBE-catalyzed oxidative kinetic resolution of racemic 1-benzyl-
THIQs by C-C bond formation for the synthesis of enantiopure (S)-berbine 
derivatives [162] 
A follow-up study by Resch et al.[163] demonstrated that the 
regioselectivity of the products formed as a consequence of BBE-
catalyzed cyclization is influenced by the substitution pattern of 
the substrate, the pH of the reaction medium and the type and 
amount of co-solvents used. It is worth noticing that the 9-hydroxy, 
and not 11-hydroxy regioisomers of tetrahydroprotoberberine 
derivatives are produced from racemic 1-benzyl-THIQ substrates 
following their cyclization by BBE (Figure 23). Resch et al.[163] 
attempted to completely switch the regioselectivity of BBE by 
medium engineering and by blocking the usual site of C±C 
FRXSOLQJ ZLWK D ÀXRUR PRLHW\ 7KH EORFNLQJ RI WKH ³QRUPDO´
reaction centre with a fluoro moiety achieved a complete switch 
in regioselectivity, leading to the formation of excellent yields (32±
50%) of the (S)-11-hydroxy functionalized protoberberines and 
the remaining (R)-benzylisoquinolines. It was notable that 
notwithstanding the change in regioselectivity, the 
enantioselectivity of the products was fully conserved (>97% ee) 
and such strategies hold considerable promise for the generation 
of enantiomerically pure novel berberine and benzylisoquinoline 
derivatives[163,164]  (Figure 23). 
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Figure 23. BBE-catalyzed oxidative kinetic resolution of racemic 1-benzyl-
THIQs by C-C bond formation to generate enantiopure (S)-9-
hydroxyprotoberberines as major products and B) complete switch in the 
regioselectivity of BBE by EORFNLQJ WKH ³QRUPDO´ UHDFWLRQFHQWHUZLWKD IOXRUR
moiety [163] 
Recently, Gandomkar et al.[165] have demonstrated the 
novel N-dealkylation function of BBE. Since the previous studies 
have shown that BBE could enatioselectively transform the 
various N-methyl reticulines to the corresponding berberines,[160] 
the authors expected that N-ethyl derivatives could also be 
accepted as substrates.  Surprisingly, the reaction of BBE with N-
ethyl-1-benzyl-1,2,3,4-THIQ derivatives did not form a new C-C- 
bond, however, BBE catalyzed the N-dealkylation of these 
substrates to form the corresponding secondary amines, leaving 
behind the unreacted (R)-substrate in enantiopure form (Figure 
24). Furthermore, the enantioselective N-dealkylation of two 
substrates was performed on a preparative scale (171 and 81 mg), 
which yielded corresponding secondary amine products with 
good yields and excellent stereoselectivity [ee >98%][165] (Figure 
24).  
 
 
Figure 24. A) BBE-catalyzed enantioselective dealkylation of rac-N-ethyl-1-
benzyl-THIQs to corresponding (S)-N-dealkylated secondary amines and (R)- 
N-ethyl-1-benzyl-THIQs; B) Preparative scale enantioselective N-dealkylation 
by BBE [165] 
Though various non-natural substrates have been reported to be 
successfully transformed to their corresponding (S)-berberine 
derivatives by BBE, it must be noted that BBE is highly 
stereoselective in nature. As BBE can accept only (S)-epimers of 
the substrates, the maximum theoretical yield of product 
formation from the racemic substrates is 50%.[127] To overcome 
the limitation of kinetic resolution, Schrittwieser et al. recently 
performed a chemo-enzymatic deracemization strategy by 
employing simultaneous kinetic resolution and stereoinversion 
using a cascade of MAO and BBE.[166] Transformation of rac-
benzylisoquinolines to optically pure (S)-berbines was reported 
using this strategy. Initially, (R)-benzylisoquinoline substrates 
were oxidized by MAO-N-11 to form the corresponding achiral 
iminium intermediates. These iminium intermediates were non-
stereoselectively reduced by chemical reductant morpholine 
borane to form the (S)-epimers of the substrates, which could 
subsequently be transformed to the corresponding (S)-berberine 
products by BBE-catalyzed cyclization. Furthermore, this process 
could be successfully carried out on a preparative scale (150-165 
mg substrate), wherein enantiomerically pure (S)-berberine 
derivatives were produced with excellent yields (up to 98% 
conversion and up to 88% isolated yields) and enantioselectivity 
(ee > 97%)[127,166](Figure 25) 
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Figure 25. Deracemization of rac-1-benzyl-THIQs to enantiopure (S)-berbines 
using a cascade of MAO/BBE/ boranes [166] 
The formation of C-C bonds plays a critical role in the 
connection of smaller substructures in order to synthesize 
complex organic structures and the carbon backbone of organic 
molecules.[20,167,168] Although challenging, the generation of 
multifunctional products is of enormous value.[127] Subsequently, 
various sophisticated enzymatic and chemo-enzymatic for the 
synthesis of complex compounds, such as pharmaceutically 
important alkaloids have been developed.[127] 
The nomenclature committee of the International Union of 
Biochemistry and Molecular Biology maintains a database of 
enzymes (http://www.enzyme-database.org) that categorizes the 
enzymes possessing unique catalytic activities. BBE, a member 
of this enzyme database, is an important enzyme that catalyzed 
an important reaction in the biosynthesis of the alkaloids 
EHORQJLQJWRWKHµprestigious scaffold¶7+,4[145,169]  
Advances achieved regarding the BBE crystallization, and 
structural and mechanistic insights have significantly broadened 
the catalytic scope of the BBE, which in turn can be used for the 
synthesis of large libraries of unnatural alkaloids with improved or 
novel biological activities.[34] The enzymatic reactions catalyzed 
by BBE have been successfully integrated for the development of 
the total chemical syntheses of alkaloids and their precursors.[86] 
Further improvement such as enantioselective 
dealkylation[165] and deracemization using enzyme cascades,[166] 
in order to expand the scope of C-C bond formation, has recently 
been achieved. These approaches have also been verified at the 
preparative scale implying their applicability at industrial scale. 
 The structural details of BBE have revealed the 
presence of typical FAD-binding domain and substrate binding 
GRPDLQ>µ%%(-GRPDLQ¶@DIHDWXUHRIWKLVIDPLO\WKDWGLVWLQJXLVKHV
it from the other sub-families of the superfamily of FAD-linked 
oxidases. The research efforts in the recent years have 
GLVFRYHUHGPDQ\KRPRORJRXVSURWHLQVWKHµ%%(-OLNHHQ]\PHV¶
The ever-increasing number of uncharacterized BBE-like 
enzymes will witness an expansion of reactions involved in the 
biosynthesis of important alkaloids in the near future.[170,171] 
4. Summary and outlooks 
The formation of C-C bond plays a critical role in the 
connection of smaller substructures in order to synthesize 
complex organic structures such as alkaloids.[167] The last few 
years have witnessed tremendous achievements in the 
understanding of the catalytic mechanisms and substrate scope 
of C-C bond forming enzymes such as the Pictet-Spenglerases 
and BBEs. Protein engineering techniques have been 
progressively used for the synthesis of large libraries of unnatural 
alkaloids with improved or novel biological activities.[34] 
Furthermore, structure-guided engineering also has been 
successfully utilized to extend the synthesis of alkaloids in 
microbial systems.[4,7,9,117,118] For instance, some of the steps in 
industrial production of terpenoid artemisinin are conducted in 
engineered yeast.[172] The near future of alkaloid syntheses 
should see the judiciously designed metabolic pathways as an 
opportunity to advance LQ WKLV µJROGHQ DJH¶ RI QDWXUDO SURGXFWV
drug discovery.[173] The well-known plasticity of few of the C-C 
bond forming enzymes is now being exploited. For instance, 
despite of the previously reported exclusive formation of S-
configured products by STRs, the recently reported access to R-
configured products will further strengthen the enzymatic toolbox 
for the synthesis of pharmaceutically important alkaloids.[73] With 
advances in the protein engineering techniques, and discovery of 
novel enzymes, it can be anticipated that major bottlenecks, for 
instance, restricted scope of amine substrates for NCSs towards 
amines, issues related with scalability, can be tackled 
efficiently.[174] Although many of the biocatalytic reactions 
employing these C-C bond forming enzymes have been 
demonstrated at smaller scales, few of them have also been 
successfully carried out at liter-scales,[107] implying their potential 
at industrial scales in near future.     
Recent years have seen the applications of elegant multi-
enzymatic strategies, wherein the C-C bond formation reactions 
catalyzed by these enzymes have been successfully integrated 
with other enzymatic reactions or chemical synthetic methods for 
the generation of a diverse array of alkaloids or their precursors. 
Moreover, the successful demonstration of these enzymatic 
approaches at the preparative scale has already proven their 
industrial potential. The enzymatic pool for the synthesis of 
pharmaceutically important enantiopure alkaloids has been 
significantly widened and C-C bond forming enzymes such as 
Pictet-Spenglerases and BBEs are currently serving as effective 
alternatives to the traditional approaches of alkaloid synthesis. 
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